References
- Henner N, Davis JM. Etiology and pathogenesis. In: Donn SM, Sinha SK, editors. Manual of neonatal respiratory care. 3rd edition. Springer Science+Business Media; New York: 2012. p. 625-31
- Consensus statement Pulmonary Hypertension Association. Available from: www.PHAssociation.org [Last accessed 27 March 2014]
- Porta NF, Steinhorn RH. Pulmonary vasodilator therapy in the NICU: inhaled nitrirc oxide, sildenafil and other pulmonary vasodilating agents. Clin perinatol 2012;39(1):149-64
- Ashman MJ, Witjes BC, Wildschut ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed 2010;95:F109-14
- Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009;155:841-7
- Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009;85:56-63
- Study of sildenafil to treat newborns with persistent pulmonary hypertension. Available from: http://clinicaltrials.gov/ct2/show/NCT01409031
- Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-10
- Mourani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84
- Berkelharmer SK, Mestan KK, Steinhorn RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 2013;37:124-31
- Noori S, Friedlich P, Wong P, et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 2007;91:92-100
- FDA drug safety communication. Available from: www.fda.gov/Drugs/DrugSafety/ucm317123.htm
- Robyn JB, Maurice B, Tomas P, on behalf of the START-2 investigators. 2014. [ Epub ahead of print]
- Circulation. Available from: circ.ahajournals.org/content/early/2014/03/17/CIRCULATIONAHA.113.005698
- FDA clarifies warning about pediatric use of revatio (sildenafil) for pulmonary arterial hypertension. Available from: www.fda.gov/Drugs/DrugSafety/ucm390876.htm
- Baker CD, Abman SH, Mourani PM. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Pediatr Allergy Immunol Pulmonol 2014;27:8-16
- del Cerro MJ, Sabate RA, Carton A, et al. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr Pulmonol 2014;49:49-59
- Ambalavanan N, Mourani P. Pulmonary hypertension in bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014;100:240-6
- Information for Healthcare Professionals: Sildenafil (marketed as Viagra and Revatio), Vardenafil (marketed as Levitra), Tadalafil (marketed as Cialis). Available from: www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124841.htm
- Sildenafil citrate (marketed as Viagra) Information for Healthcare Professionals (7/2005). Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm162862.htm
- Fang AY, Guy KJ, König K. The effect of sildenafil on retinopathy of prematurity in very preterm infants. J Perinatol 2013;33(3):218-21
- Pierce CM, Petros AJ, Fielder AR. No evidence for severe retinopathy of prematurity following sildenafil. Br J Ophthalmol 2005;89(2):250